Compare OBK & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | ABCL |
|---|---|---|
| Founded | 1912 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2018 | 2020 |
| Metric | OBK | ABCL |
|---|---|---|
| Price | $43.97 | $3.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $44.29 | $7.75 |
| AVG Volume (30 Days) | 234.5K | ★ 3.8M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | ★ $28,833,000.00 |
| Revenue This Year | $25.48 | $26.18 |
| Revenue Next Year | $5.79 | $13.51 |
| P/E Ratio | $30.12 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.80 | $1.89 |
| 52 Week High | $46.02 | $6.52 |
| Indicator | OBK | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 40.69 |
| Support Level | $42.75 | $3.06 |
| Resistance Level | $45.05 | $3.24 |
| Average True Range (ATR) | 1.24 | 0.21 |
| MACD | -0.29 | -0.01 |
| Stochastic Oscillator | 20.49 | 39.68 |
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.